Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01137032 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
A Phase 4 study of Atopic Dermatitis and Psoriasis, sponsored by Fougera Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT01137032 is a Phase 4 study of Atopic Dermatitis and Psoriasis that has completed, run by Fougera Pharmaceuticals. The registered enrollment target is 19 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01137032, a Phase 4 study of Atopic Dermatitis and Psoriasis, has completed, sponsored by Fougera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.
Conditions Studied
Interventions
- DRUG Pandel Cream 0.1%
Study Locations (3)
Nebraska
- Christopher Huerter, MD - Omaha
South Carolina
- Oswald Mikell, MD - Hilton Head Island
Tennessee
- Michael Gold, MD - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01137032
The ClinicalTrials.gov registry entry for NCT01137032 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (97% lower). The listed sponsor is Fougera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Pandel Cream 0.1% is the first listed.
NCT01137032 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Nebraska, South Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01137032 about?
NCT01137032 is a clinical study titled "Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population". The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.
What is the current status of trial NCT01137032?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2004-06. Estimated completion is 2005-08.
What conditions does trial NCT01137032 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis.
What interventions are being tested in trial NCT01137032?
The interventions under investigation include: Pandel Cream 0.1% (DRUG).
Who is sponsoring clinical trial NCT01137032?
This trial is sponsored by Fougera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01137032 being conducted?
This trial has 3 study locations across Nebraska, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.